BioMed X expands research partnership with Merck KGaA
Will closely examine DNA damage response in hopes of improving cancer treatment options
BioMed X, an independent research institute, revealed the start of its eighth joint research program with Merck KGaA, Darmstadt, Germany. The new program will dive into the role of extrachromosomal DNA in cancer and it will complement the research of two ongoing oncology programs at BioMed X in the fields of DNA damage response and RNA splicing.
Extrachromosomal circular DNA (ecDNA) was recently found to be plentiful in multiple human cancer cells, though its frequency fluctuates between different cancer types. Elevated levels of ecDNA have been considered to be linked to poor clinical outcome in human cancers.
The main objective of this new project will be to produce an atlas of extrachromosomal DNA in human cancer tissues, to investigate how oncogenes in ecDNA could contribute to tumorigenesis, disease progression, tumor heterogeneity, metastasis and treatment resistance, and to develop novel therapeutic strategies based on oncogenic alterations in ecDNA.
“We are pleased to extend our collaboration even further in the field of cancer research,” says Christian Tidona, founder and managing director of the BioMed X Institute. “This new program will strengthen our expertise at the forefront of deep cancer biology which can potentially lead to better treatment options for patients.”
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
